News
For more news, follow us on Twitter.
Mortality risk after use of a paclitaxel-coated stent in femoropopliteal peripheral artery disease
Posted on January 22, 2021
Although paclitaxel-based devices which demonstrated improved outcomes in the treatment of lower-extremity peripheral artery disease (PAD) have been used worldwide, Katsanos et al. reported a systematic review and summary-level meta-analysis of RCTs in which application of paclitaxel-based devices in the femoropopliteal artery was associated with an increased mortality risk…
Localized inhibition of platelets and platelet derived growth factor by a matrix targeted glycan mimetic significantly attenuates liver fibrosis
Posted on November 17, 2020
New therapeutic strategies are needed for the growing unmet clinical needs in liver disease and fibrosis. Platelet activation and PDGF activity are recognized as important therapeutic targets; however, no therapeutic approach has yet addressed these two upstream drivers of liver fibrosis. We therefore designed a matrix-targeting glycan therapeutic, SBR-294, to inhibit collagen-mediated platelet activation while also inhibiting PDGF activity…
Symic Bio Announces Last Patient Enrolled in Osteoarthritis Phase
2b Study MODIFY3
Posted on October 8, 2020
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that the last patient had been enrolled in its Phase 2b OA (osteoarthritis) study. The study, dubbed MODIFY3, is a double-blinded, randomized controlled trial investigating Symic Bio’s DMOAD (diseasemodifying OA drug) candidate, SB-061 vs. placebo control…
Symic Bio Announces First Patient Enrolled in Osteoarthritis Phase
2b Study
Posted on March 1, 2020
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that the first patient had been enrolled in its Phase 2b OA (osteoarthritis) study. The study, dubbed MODIFY3, is a doubleblinded, randomized controlled trial investigating Symic Bio’s DMOAD (disease-modifying OA drug) candidate, SB-061 vs. placebo control…
Symic Bio CSO Glenn Prestwich, PhD, elected to American Association for the Advancement of Science
Posted on November 27, 2018
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Glenn Prestwich, PhD, Chief Scientific Officer of Symic Bio, was elected a fellow of the American Association for the Advancement of Science. Dr. Prestwich has been about encountering problems in biology and medicine and innovating solutions using chemistry for almost 50 years…
Symic Bio Selected for “The Best of The Liver Meeting 2018” at AASLD
Posted on November 9, 2018
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that they were selected for “The Best of The Liver Meeting 2018” at the AASLD international liver meeting and will be presenting on its liver fibrosis program at the upcoming conference in San Francisco. Symic’s molecule, SBR-294, is unique in both its molecule class as well as in its approach to treating liver disease…
Symic Bio to Present at the 10th Annual ChinaBio Partnering Forum
Posted on April 18, 2018
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Rinko Ghosh, President and Chief Business Officer, will present an overview of the company pipeline at the 10th Annual ChinaBio Partnering Forum being held April 25-26, 2018, in Suzhou, China…
Results from Symic Bio Liver Fibrosis Program Presented at the International Liver Congress 2018
Posted on April 16, 2018
Symic Bio, a biopharmaceutical company developing novel biotherapeutics targeting the extracellular matrix, presented results from a lead candidate therapy for liver fibrosis at the International Liver Congress 2018, the annual meeting of the European Association for the Study of the Liver, held April 11-15, 2018, in Paris. Results demonstrated that treatment with matrix-targeting therapeutic candidate SBR-294 resulted in decreased liver fibrosis in two distinct preclinical models of liver fibrosis…
Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease
Posted on April 2, 2018
Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced 12-month results from the Phase 1/2 SHIELD trial evaluating SB-030 in patients with peripheral vascular disease undergoing angioplasty. Under an extended trial protocol allowing assessment of secondary endpoint measurements at 12 months following intervention, patients in the treatment group demonstrated a clinically meaningful and statistically significant 23 percent reduction in index limb re-intervention as compared with the control group (p=0.025)…
Symic Bio to Present at the BioCentury 25th Annual Future Leaders Conference in New York
Posted on March 15, 2018
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline at the BioCentury 25th Annual Future Leaders in the Biotech Industry Conference in New York…
Symic Bio Announces Results of Locally-Administered Therapeutic SB-030 in Preclinical Model of Vascular Intervention
Posted on March 5, 2018
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced results from a preclinical study of locally-applied therapeutic SB-030 in the reduction of inflammatory response and clot formation. In a porcine arteriovenous shunt model for vascular procedures such as bypass grafts and angioplasty, extracorporeal stents coated with collagen and treated with SB-030 showed significantly reduced adherent platelets as compared with stents treated with a saline control…
Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis
Posted on February 7, 2018
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced topline results from the MODIFY2 Phase 2 clinical trial of SB-061 for symptom management in mild-to-moderate osteoarthritis of the knee. The 12-week, multicenter, double-blind trial of 60 patients was designed to investigate the effects of SB-061 in the overall population as well as a prespecified subpopulation of patients with knee effusions. MODIFY2 demonstrated that treatment with SB-061 was well-tolerated, with a safety profile consistent with the saline control treatment group…
Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology
Posted on January 22, 2018
Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced the appointment of Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology. With this appointment, Dr. Alaoui will lead research into the identification and characterization of novel therapeutics enabled by the Symic Bio platform…
Symic Bio to Present at Upcoming Conferences in London and New York
Posted on November 9, 2017
Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced that Ken Horne, chief executive officer, will present at the upcoming 2017 Biotech and Money Inv€$tival Showcase, organized in partnership with Jefferies LLC, and the Trout Group EU Company Showcase in London. In addition, Ken Horne will present an overview of the company platform and clinical development programs at the Piper Jaffray 29th Annual Healthcare Conference in New York. The company also plans to attend the Jefferies 2017 London Healthcare Conference taking place Nov. 15-16, 2017…
Symic Bio Appoints Wayne Froland, Ph.D., as Executive Vice President of Technical Operations
Posted on November 3, 2017
Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, announced today the appointment of Wayne Froland, Ph.D., as Executive Vice President of Technical Operations. Dr. Froland has over 20 years of experience in industry primarily focusing on process development in biopharmaceutical manufacturing…
Symic Bio Announces Results from the Phase 1/2 SHIELD Trial of SB-030 in Peripheral Vascular Disease
Posted on November 1, 2017
Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced results from the Phase 1/2 SHIELD trial evaluating SB-030, a locally administered therapeutic, in patients with peripheral vascular disease undergoing angioplasty. In this first-in-human, prospective, randomized, single-blind controlled study of 67 patients, SB-030 demonstrated a positive safety profile, with no clinically meaningful difference observed in adverse events between treatment and control groups…
Symic Bio to Present at Upcoming Conferences in Tokyo and Berlin
Posted on October 23, 2017
Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that the company will present at the following conferences…
Symic Bio to Present at Upcoming October Conferences
Posted on October 2, 2017
Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that Rinko Ghosh, President and Chief Business Officer, will present at the following conferences in October…
Symic Bio to Present at the Ladenburg Thalmann 2017 Annual Healthcare Conference
Posted on September 18, 2017
Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline at the Ladenburg Thalmann 2017 Healthcare Conference in New York…
Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis
Posted on August 23, 2017
Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061 for pain management in mild-to-moderate osteoarthritis of the knee. The initiation of the 12-week, multicenter, double-blinded trial of approximately 60 patients follows previously announced Phase 1/2a clinical results supporting the safety, tolerability and intended mechanism of action of SB-061…
Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry
Posted on July 5, 2017
Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, announced today the appointment of Glenn Prestwich, Ph.D., as Executive Vice President of Chemistry. Dr. Prestwich, Presidential Professor of Medicinal Chemistry at the University of Utah and former member of the Symic Bio Scientific Advisory Board, will assume a direct executive role in the advancement of the company’s platform of clinical-stage therapeutics and in the expansion of its pipeline…
Symic Bio Secures $30 Million Series B Financing and Provides SB-030 Program Update
Posted on May 22, 2017
Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, today announced the successful completion of a $30 million Series B financing and provided a program update regarding lead program SB-030. The Series B financing involved participation of all current major investors as well as new investor HEDA Ventures…
Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee
Posted on May 18, 2017
Symic Bio, a biopharmaceutical company developing novel matrix regulator therapeutics, today announced topline results from the Phase 1/2a MODIFY-OA trial of SB-061, an intra-articular treatment for osteoarthritis of the knee. SB-061 was shown to be safe and very well-tolerated with no drug-related serious adverse events and a very low rate of local adverse events (4.1 percent)…
Symic Bio to Present at the 11th Annual BIO-Europe Spring Conference
Posted on March 13, 2017
Symic Bio, a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics, today announced that Rinko Ghosh, President and Chief Business Officer, will present an overview of current programs at the upcoming 11th Annual BIO-Europe Spring Conference…
Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease
Posted on February 24, 2017
Symic Bio, a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics, announced today the completion of enrollment for the SHIELD clinical trial of SB-030 in peripheral artery disease. The trial will evaluate the safety and efficacy of SB-030, a locally administered single-use therapeutic, in the reduction of restenosis following angioplasty…
Symic Bio to Present at Upcoming Conferences
Posted on February 6, 2017
Symic Bio, a clinical-stage biotech company that is developing a new category of therapeutics focused on matrix biology, today announced that Ken Horne, Chief Executive Officer, will present at the BIO CEO & Investor Conference 2017 and the Cowen Health Care Conference…
Symic Bio Appoints Scott W. Morrison to Board of Directors
Posted on January 30, 2017
Symic Bio, a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics, today announced the appointment of Scott W. Morrison to its Board of Directors. Mr. Morrison was U.S. Life Sciences Leader at Ernst & Young LLP until his retirement in December 2015…
Symic Bio to Participate in the 2017 East/West CEO Conference
Posted on January 3, 2017
Symic Bio, a clinical stage biopharmaceutical company focused on matrix biology developing a new category of therapeutics, today announced that Ken Horne, Chief Executive Officer, will participate in the 2017 East/West CEO Conference on a panel entitled “Global Perspectives on Funding and Innovation”…
Symic Bio to Present at the 28th Annual Piper Jaffray Healthcare Conference
Posted on November 22, 2016
Symic Bio, a clinical stage biopharmaceutical company focused on extracellular matrix biology developing a new category of therapeutics, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline and progress at the upcoming Piper Jaffray Healthcare Conference…
Symic Bio and Nordic Bioscience Complete Enrollment of MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis
Posted on November 10, 2016
Symic Bio, a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, announced today the completion of enrollment for its Phase 1/2a MODIFY-OA clinical trial of SB-061 in the treatment of osteoarthritis of the knee. Top-line results from the trial are expected to be announced in the first half of 2017…
Symic Bio to Present at the 22nd Annual BIO Europe Conference
Posted on November 2, 2016
Symic Bio, a clinical-stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, today announced that Rinko Ghosh, President and Chief Business Officer, will present at the 22nd Annual BIO Europe Conference in Cologne. The presentation will take place within the autoimmune/inflammation track…
Symic Bio Appoints Morten Karsdal, Ph.D., to Scientific Advisory Board
Posted on October 19, 2016
Symic Bio, a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, today announced that Morten Karsdal, Ph.D., has been appointed as a member of the company’s Scientific Advisory Board…
Symic Bio to Present at the 15th Annual BIO Investor Forum
Posted on October 11, 2016
Symic Bio, a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, today announced that Ken Horne, Chief Executive Officer, will present at the upcoming BIO Investor Forum conference…
Thomas N. Wight, Ph.D., Joins Symic Bio Scientific Advisory Board
Posted on September 13, 2016
Symic Bio, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Thomas N. Wight, Ph.D., Director of the Matrix Biology Program at the Benaroya Research Institute and Affiliate Professor of Pathology at the University of Washington, has been appointed as a member of the company’s Scientific Advisory Board…
Symic to Present at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference
Posted on August 29, 2016
Symic, a clinical stage biotherapeutics company developing therapies inspired by naturally occurring molecules of the extracellular matrix, today announced that Ken Horne, Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference…
Symic Appoints Carolyn Bertozzi, Ph.D., to Scientific Advisory Board
Posted on June 28, 2016
Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Carolyn Bertozzi, Ph.D., has been appointed as a member of the company’s Scientific Advisory Board…
Symic Appoints Manish Anand as Vice President of Regulatory Affairs and Quality
Posted on June 20, 2016
Symic, a clinical stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix, today announced the appointment of Manish Anand as Vice President of Regulatory Affairs and Quality. Mr. Anand will lead the company’s regulatory strategy, global filings and quality efforts…
Symic Advances Product Candidate SB-061 into Clinical Development for the Treatment of Osteoarthritis
Posted on June 13, 2016
Symic, a clinical stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the treatment of the first patient in the MODIFY-OA Clinical Trial (Study to Measure the Safety and Efficacy Outcome after Intra-articular Delivery of SB-061 versus Control in Symptomatic Osteoarthritis Patients) investigating SB-061, a novel and proprietary treatment specifically developed for acute management of osteoarthritis (OA) pain…
Symic Appoints Alyssa Panitch, Ph.D., as Chair of Scientific Advisory Board
Posted on June 1, 2016
Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Alyssa Panitch, Ph.D., one of the founders of the company and an inventor of Symic’s technology, has been appointed to chair the company’s Scientific Advisory Board…
Symic to Present at the Boston Biotech CEO Conference
Posted on May 24, 2016
Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Ken Horne, Chief Executive Officer, will present at the Boston Biotech Conferences Boston CEO Conference as part of the session “Next Generation Biotech CEOs and Board Members”…
Symic to Present at Upcoming May Conferences
Posted on May 4, 2016
Symic, a clinical stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix, today announced that Jocelyn Jackson, Chief Financial Officer, will present at BioEquity Europe 2016 in Copenhagen and the Bay Area Biotech Forum in San Francisco…
Symic Appoints Kathleen Gogas, Ph.D., as VP of Preclinical Development
Posted on April 21, 2016
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target the extracellular matrix, today announced the appointment of Kathleen Gogas, Ph.D., as Vice President of Preclinical Development. Dr. Gogas will lead the company’s research efforts in preclinical pharmacology and oversee IND enabling research…
Symic to Present at the BIO Europe Spring Conference
Posted on March 29, 2016
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Rinko Ghosh, President and Chief Business Officer, will present at the BIO Europe Spring Conference in Stockholm…
Symic to Present at the 13th Annual BIO Asia International Conference
Posted on March 10, 2016
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 13th Annual BIO Asia International Conference in Tokyo…
Symic to Present at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference
Posted on March 1, 2016
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York…
Symic to Present at the 18th Annual BIO CEO & Investor Conference
Posted on February 2, 2016
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference in New York…
Symic Appoints Rinko Ghosh President and Chief Business Officer
Posted on January 7, 2016
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the appointment of Rinko Ghosh as President and Chief Business Officer…
Symic Receives New U.S. Patent for Osteoarthritis Program
Posted on December 16, 2015
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that it continues to fortify the patent protection covering its proteoglycan-based therapeutic platform with U.S. Patent No 9,217,016, which will be issued on Dec. 22, 2015. This patent covers SB-061, a compound that mimics the protective proteoglycan, aggrecan, to reduce cartilage degradation and pain in patients with osteoarthritis (OA)…
Symic Appoints Seema Kantak, Ph.D., Chief Scientific Officer
Posted on December 10, 2015
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the appointment of Seema Kantak, Ph.D., as Chief Scientific Officer…
Symic to Present at the 27th Annual Piper Jaffray Healthcare Conference
Posted on December 1, 2015
Symic Bio, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, with present at the 27th Annual Piper Jaffray Healthcare Conference in New York…
Symic Secures $25 Million in Series A-2 Financing to Advance Clinical-Stage Biotherapeutics Platform
Posted on December 1, 2015
Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that it has secured $25 million in a Series A-2 financing to advance the company’s pipeline, including its lead candidates SB-030 and SB-061. The financing was led by Lilly Ventures and includes the participation by all existing major investors, as well as several new investors. This new funding brings the total capital raised by Symic to over $43 million since being founded in 2012…
Symic Bio Selects Osteoarthritis Clinical Candidate
Posted on November 17, 2015
Symic Bio, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the selection of SB-061 as the company’s first osteoarthritis clinical candidate. In preclinical studies, SB-061 was shown to reduce pain and cartilage degradation in models of osteoarthritis. SB-061, which will be administered as an intra-articular injection, is designed to prevent the degradation of cartilage by mimicking the protective effect of the proteoglycan aggrecan…
Symic Bio Appoints Kamal Egodage, Ph.D., MBA, VP of Development & Manufacturing and Grace Wong-Sarad, VP and Controller
Posted on November 5, 2015
Symic Bio, a clinical-stage biotherapeutics company developing multiple compounds that target the extracellular matrix (ECM), today announced the appointment of Kamal Egodage, Ph.D., MBA, as Vice President of Development & Manufacturing and Grace Wong-Sarad as Vice President and Controller…
Symic Bio Advances First Product Candidate, SB-030, into Clinical Development with Treatment of First Patient in SHIELD Trial
Posted on October 27, 2015
Symic Bio, a clinical-stage biotherapeutics platform company developing compounds that target the extracellular matrix (ECM), today announced the treatment of the first patient in its Phase 1/2 clinical Study in Humans to Investigate the Efficacy and Safety of Luminal SB-030 Delivery in Peripheral Artery Disease (SHIELD Trial). The study will evaluate the safety and efficacy of SB-030 (previously SBCV-030), a locally applied, single-use treatment for the reduction of neointimal hyperplasia resulting from the vascular injury following percutaneous transluminal angioplasty (PTA)…
Symic Bio Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD
Posted on August 26, 2015
Platform therapeutic company Symic Bio, Inc. (“Symic”) announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health (NIH) to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis…
Symic Bio Selects Vascular Clinical Candidate
SBCV-030 Prevents Platelet-Initiated Neointimal Hyperplasia Cascade
Posted on July 20, 2015
Symic Bio announced today the selection of SBCV-030 as the clinical candidate for the company’s first vascular program. In preclinical studies SBCV-030 inhibits the scarring response that occurs when a vessel is injured. Initially, clinical indications where acute injuries are caused by vascular surgery or percutaneous intervention will be pursued. SBCV-030 will be delivered locally at the time of the procedure. SBCV-030 will be first investigated in peripheral arterial disease, or PAD, a disease that affects approximately eight million Americans according to the Center for Disease Control, or CDC…
Symic Bio Announces Appointment of Barbara Yanni and Bill Newell as Independent Directors to its Board
Posted on February 23, 2015
Symic Bio announced today the appointment of Barbara Yanni and William J. Newell to its board of directors. Mr. Newell is the CEO of Sutro Biopharma, Inc. which has entered into a strategic collaboration and acquisition option with Celgene regarding their therapeutic technology platform. Ms. Yanni retired in 2014 from Merck & Co., Inc. where she was most recently Vice President and Chief Licensing Officer…
Symic Bio Announces Collaboration with Nordic Biosciences for its Osteoarthritis Program
Posted on January 5, 2015
Symic Bio today announced a strategic alliance with Nordic Bioscience A/S to focus on the clinical development of Symic’s osteoarthritis (OA) program. Nordic Bioscience (Copenhagen, Denmark) is a world-‐‐renowned pharmaceutical development organization…
Symic Bio Secures $15 Million in Series A Financing
Posted on January 5, 2015
Symic Bio announced today that the company has secured $15 million in Series A financing. This financing will support the company’s ongoing development of its novel therapeutics, and advancement of its two lead programs into clinical trials…